Zobrazeno 1 - 10
of 209
pro vyhledávání: ''
Autor:
Caitlin C. Murphy, Danyi Xiong, Bhumika Maddineni, Ethan A. Halm, David E. Gerber, Sandi L. Pruitt, Hong Zhu, Daniel F. Heitjan, Anna Tavakkoli, Amit G. Singal
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 14, Pp 4752-4767 (2021)
Cancer Medicine, Vol 10, Iss 14, Pp 4752-4767 (2021)
Patients with previous cancer are often excluded from clinical trials despite limited evidence about their prognosis. We examined the effect of previous cancer on overall and colorectal cancer (CRC)‐specific survival of patients newly diagnosed wit
Autor:
Ilaria Portarena, Gianluca Vanni, Stefano Rizza, Tommaso Perretta, Marco Pellicciaro, Chiara Adriana Pistolese, Oreste Claudio Buonomo, Domiziana Pedini, Chiara Buonomo, Marco Materazzo
Publikováno v:
Anticancer Research. 41:2689-2696
BACKGROUND/AIM: The COVID-19 lockdown includes restrictive measures and temporary health system reorganization. Resources were shifted to COVID-19 patients, screening programs were temporary suspended, and oncological care suffered slow-down. The aim
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose Several studies have evaluated the role of delayed initiation of adjuvant chemotherapy (AC) in breast cancer (BC), but the results have remained controversial and an optimal time has not been defined. Our aim was to determine the effect of ti
Autor:
Susan Abughosh, Meghana V. Trivedi, Kelvin Lu, Rutugandha Paranjpe, Carine Opsomer, Hanna Zaghloul, Grace S. Hwang, Uzoamaka Abajue
Publikováno v:
Clinical Breast Cancer. 20:520-526
Introduction Adherence to oral endocrine therapy (OET) reduces recurrence risk for hormone receptor (HR)-positive breast cancer (BC). Refill data accessed through electronic health records may provide objective assessment of OET adherence. Our goal w
Autor:
Daniel C. Danila, Thompson N. Doman, Jonathan Landa, David Schaer, Shanu Modi, Elizabeth A. Comen, Matthew Adamow, Jill S. Gluskin, Susan F. Slovin, Michael J. Morris, Suhyun Kang, Manisha Brahmachary, Sonya C. Chapman, David M. J. Hoffman, Rachel Sanford, Jeremy C. Durack, Josef J. Fox, Michelle Carlsen, Ruslan D. Novosiadly, Philomena McAndrew, John S. Kauh, Dana E. Rathkopf, Courtney M. Tate, Danni Yu, Karen A. Autio, Victoria S. Blinder, Phillip Wong, Praneet Kang, Christopher A. Klebanoff, Heather L. McArthur
Publikováno v:
Clin Cancer Res
Purpose: Tumor-associated macrophages correlate with increased invasiveness, growth, and immunosuppression. Activation of the colony-stimulating factor-1 receptor (CSF-1R) results in proliferation, differentiation, and migration of monocytes/macropha
Publikováno v:
Anticancer Research. 40:5229-5235
Background/aim The prolactin receptor (PRLR) is implicated in the tumorigenesis of breast and prostate cancers where it drives cell proliferation, survival, and migration. LFA102 is a humanized monoclonal antibody against PRLR with promising preclini
Autor:
E. Shelley Hwang, Terry Hyslop, Rachel A. Greenup, Jennifer K. Plichta, Rebecca Vernon, Oluwadamilola M. Fayanju, Samantha M. Thomas, Laura H. Rosenberger
Publikováno v:
Breast Cancer Res Treat
BACKGROUND: Given presumed differences in disease severity between young (≤ 45 years) and elderly (≥ 75 years) women with breast cancer, we sought to compare tumor histopathology, stage at presentation, patterns of care, and survival at the extre
Publikováno v:
Breast Cancer Research and Treatment. 180:87-95
Squamous cell carcinoma (SCC) of the breast is a rare entity of breast cancer, with a very poor prognosis, and whose pathophysiology is still unwell established. Therapeutic management is very heterogeneous due to its incomplete understanding. Nevert
Autor:
Tuya Pal, Christina E. Bailey, Wei Zheng, Ingrid A. Mayer, Xiao-Ou Shu, Ingrid M. Meszoely, Ben Ho Park, Fei Wang, Sonya Reid
Publikováno v:
Clin Cancer Res
Purpose: Prognostic value of Oncotype DX Breast Recurrence Score (RS) in male patients with breast cancer is understudied. We evaluated associations of RS with overall mortality in male patients with breast cancer and compared it with female counterp
Autor:
Prabhat Singh Malik, S V Suryanarayana Deo, Ajay Gogia, Sandeep Mathur, Rakesh K. Phulia, Dayanand Sharma, Sanjay Thulkar
Publikováno v:
Journal of Global Oncology
Journal of Global Oncology, Vol 5, Pp 1-8 (2019)
Journal of Global Oncology, Vol 5, Pp 1-8 (2019)
PURPOSE Biomarker—estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/ neu) —discordance plays an essential role in the management and prognosis of patients with metastatic breast cancer. Rates o